Byetta diabetes drug subject to warnings

According to reports circulating the diabetes media, the Food and Drug Administration has this week strengthened warnings regarding type 2 diabetes drug Byetta .
The drug has reportedly been associated with dangerous pancreatic inflammation, and has caused both hospitalisations and death. The FDA has received six reports of major problems, with two cases proving fatal.
If pancreatitis is suspected, the FDA made clear, Byetta should be discontinued. If pancreatitis is confirmed, the drug should not be confirmed. The FDA approved Byetta in 2005, when the drug was promised as a miracle fix due to its weight loss side effects for diabetics .
Amylin denied that diabetic patients taking Byetta were at a greater risk of pancreatitis .